cefuroxime axetil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	566	64544-07-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefuroxime axetil cefazine altacef ceftin cefurax oraxim	Molecular weight: 510.47 Formula: C20H22N4O10S CLOGP: 0.90 LIPINSKI: 2 HAC: 14 HDO: 2 TPSA: 189.06 ALOGS: -3.54 ROTB: 12 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cefuroxime axetil
cefazine
altacef
ceftin
cefurax
oraxim

Molecular weight: 510.47
Formula: C20H22N4O10S
CLOGP: 0.90
LIPINSKI: 2
HAC: 14
HDO: 2
TPSA: 189.06
ALOGS: -3.54
ROTB: 12

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 28, 1987	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	145.85	18.84	152	5012	250858	50349102
Nicotine dependence	94.13	18.84	20	5144	635	50599325
Sputum purulent	86.45	18.84	20	5144	943	50599017
Secondary immunodeficiency	82.28	18.84	20	5144	1168	50598792
Anaphylactic reaction	70.39	18.84	52	5112	54003	50545957
Oesophageal pain	65.28	18.84	20	5144	2782	50597178
Oesophageal spasm	64.79	18.84	19	5145	2277	50597683
Trimethylaminuria	62.29	18.84	11	5153	127	50599833
Anaphylactic shock	60.74	18.84	33	5131	20122	50579838
Full blood count abnormal	53.54	18.84	32	5132	23356	50576604
Urticaria	50.41	18.84	64	5100	129497	50470463
Lymphoedema	45.41	18.84	21	5143	9101	50590859
Obstructive airways disorder	42.68	18.84	24	5140	15628	50584332
Pseudomembranous colitis	40.86	18.84	14	5150	2771	50597189
Product preparation issue	35.12	18.84	9	5155	652	50599308
Megacolon	34.79	18.84	11	5153	1695	50598265
Pruritus	33.68	18.84	83	5081	283485	50316475
Serous retinal detachment	32.71	18.84	7	5157	230	50599730
Rash	30.68	18.84	106	5058	437365	50162595
Dysbiosis	30.29	18.84	8	5156	652	50599308
Sleep apnoea syndrome	28.89	18.84	22	5142	23846	50576114
Macular oedema	26.61	18.84	11	5153	3643	50596317
Anterior chamber inflammation	25.84	18.84	6	5158	287	50599673
Abdominal pain	25.78	18.84	67	5097	236161	50363799
Kounis syndrome	25.73	18.84	8	5156	1167	50598793
Tinnitus	23.69	18.84	21	5143	28111	50571849
Agitation	23.33	18.84	28	5136	53356	50546604
Bronchitis	22.41	18.84	39	5125	104120	50495840
Cross sensitivity reaction	21.68	18.84	8	5156	1961	50597999
Clostridium difficile infection	21.44	18.84	19	5145	25420	50574540
Macular detachment	20.55	18.84	4	5160	81	50599879
Fibromyalgia	20.33	18.84	24	5140	44954	50555006
Asthma	19.93	18.84	34	5130	89303	50510657
Fluid retention	19.61	18.84	25	5139	50624	50549336
Retinoschisis	19.37	18.84	3	5161	14	50599946
Oesophagitis haemorrhagic	19.07	18.84	5	5159	396	50599564

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product preparation issue	85.54	21.35	15	2182	234	29572096
Macular detachment	55.58	21.35	9	2188	84	29572246
Anterior chamber inflammation	46.76	21.35	9	2188	239	29572091
Kounis syndrome	46.47	21.35	13	2184	1816	29570514
Macular oedema	42.67	21.35	13	2184	2445	29569885
Retinal toxicity	36.73	21.35	8	2189	396	29571934
Retinoschisis	36.14	21.35	5	2192	13	29572317
Metabolic disorder	26.25	21.35	10	2187	3685	29568645
Serous retinal detachment	25.59	21.35	6	2191	414	29571916
Gastrointestinal ischaemia	24.92	21.35	5	2192	165	29572165
Corneal oedema	23.99	21.35	7	2190	1135	29571195
Retinal oedema	23.85	21.35	6	2191	557	29571773
Retinal injury	23.48	21.35	4	2193	52	29572278
Anaphylactic reaction	23.23	21.35	18	2179	27555	29544775
Spinal muscular atrophy	22.32	21.35	5	2192	282	29572048

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic reaction	90.15	18.14	67	6670	68597	64423398
Drug hypersensitivity	88.23	18.14	116	6621	237699	64254296
Nicotine dependence	78.50	18.14	18	6719	796	64491199
Sputum purulent	76.15	18.14	19	6718	1207	64490788
Product preparation issue	74.69	18.14	17	6720	727	64491268
Oesophageal spasm	71.22	18.14	21	6716	2504	64489491
Macular detachment	71.20	18.14	13	6724	179	64491816
Oesophageal pain	70.06	18.14	22	6715	3241	64488754
Anterior chamber inflammation	69.94	18.14	15	6722	486	64491509
Anaphylactic shock	69.83	18.14	42	6695	30286	64461709
Macular oedema	69.06	18.14	24	6713	4843	64487152
Kounis syndrome	67.48	18.14	21	6716	3004	64488991
Trimethylaminuria	66.87	18.14	12	6725	149	64491846
Serous retinal detachment	59.69	18.14	14	6723	684	64491311
Secondary immunodeficiency	56.96	18.14	18	6719	2706	64489289
Urticaria	56.29	18.14	73	6664	147244	64344751
Retinoschisis	51.89	18.14	8	6729	35	64491960
Lymphoedema	43.29	18.14	21	6716	9884	64482111
Pseudomembranous colitis	43.03	18.14	17	6720	4899	64487096
Pruritus	42.72	18.14	98	6639	312302	64179693
Rash	40.38	18.14	122	6615	458427	64033568
Corneal oedema	38.90	18.14	13	6724	2330	64489665
Full blood count abnormal	34.52	18.14	27	6710	29730	64462265
Retinal infarction	33.76	18.14	7	6730	192	64491803
Obstructive airways disorder	33.50	18.14	24	6713	23161	64468834
Retinal oedema	33.12	18.14	9	6728	799	64491196
Dysbiosis	32.20	18.14	9	6728	886	64491109
Megacolon	31.75	18.14	12	6725	3070	64488925
Ocular toxicity	30.28	18.14	8	6729	638	64491357
Retinal toxicity	28.68	18.14	9	6728	1321	64490674
Sleep apnoea syndrome	28.14	18.14	24	6713	29808	64462187
Rash maculo-papular	25.69	18.14	28	6709	46998	64444997
Tinnitus	25.36	18.14	24	6713	34109	64457886
Fibromyalgia	22.59	18.14	23	6714	35708	64456287
Clostridium difficile infection	22.35	18.14	23	6714	36140	64455855
Bronchitis	21.78	18.14	40	6697	108703	64383292
Vomiting	21.01	18.14	113	6624	551004	63940991
Cystitis	20.89	18.14	24	6713	42651	64449344
Cross sensitivity reaction	20.54	18.14	9	6728	3358	64488637
Spinal muscular atrophy	20.50	18.14	5	6732	289	64491706
Product impurity	20.09	18.14	4	6733	89	64491906
Migraine	19.27	18.14	28	6709	62649	64429346
Gastrointestinal ischaemia	18.98	18.14	5	6732	394	64491601
Hypersensitivity	18.85	18.14	54	6683	196398	64295597
Ichthyosis	18.67	18.14	4	6733	129	64491866
Cystoid macular oedema	18.61	18.14	7	6730	1767	64490228

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA CS	M0003827	Cephalosporins
FDA EPC	N0000175488	Cephalosporin Antibacterial
CHEBI has role	CHEBI:88188	allergenic drug
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute otitis media	indication	3110003
Gonorrhea	indication	15628003	DOID:7551
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Acute gonococcal cervicitis	indication	20943002	DOID:10615
Lyme disease	indication	23502006	DOID:11729
Acute gonococcal urethritis	indication	29864006
Pneumonia due to Streptococcus	indication	34020007
Streptococcal tonsillitis	indication	41582007
Gonorrhea of rectum	indication	42746002
Impetigo	indication	48277006	DOID:8504
Lower respiratory tract infection	indication	50417007
Bacterial pneumonia	indication	53084003	DOID:874
Klebsiella cystitis	indication	60867007
Acute gonococcal endometritis	indication	65295003	DOID:7527
Acute maxillary sinusitis	indication	68272006	DOID:2050
Haemophilus influenzae pneumonia	indication	70036007
Acute bacterial sinusitis	indication	75498004
Escherichia coli urinary tract infection	indication	301011002
Streptococcus pyogenes infection	indication	302809008
Bacterial urinary infection	indication	312124009
Infective otitis media	indication	312218008
Infection due to Staphylococcus aureus	indication	406602003
Acute exacerbation of chronic bronchitis	indication	425748003
Haemophilus Influenzae Acute Otitis Media	indication
Haemophilus Influenzae Bronchitis	indication
Haemophilus Parainfluenzae Bronchitis	indication
Streptococcus Pneumoniae Chronic Bronchitis	indication
Haemophilus Parainfluenzae Chronic Bronchitis	indication
Haemophilus Influenzae Chronic Bronchitis	indication
Moraxella Catarrhalis Acute Otitis Media	indication
Streptococcus Pneumoniae Bronchitis	indication
Blood coagulation disorder	contraindication	64779008	DOID:1247
Factor II deficiency	contraindication	73975000
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.75	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR				CHEMBL	CHEMBL

External reference:

ID	Source
4017552	VUID
N0000179073	NUI
D00914	KEGG_DRUG
20493	RXNORM
4017552	VANDF
4019668	VANDF
C0055015	UMLSCUI
CHEBI:3516	CHEBI
CHEBI:3515	CHEBI
KOV	PDB_CHEM_ID
CHEMBL1095930	ChEMBL_ID
C040738	MESH_SUPPLEMENTAL_RECORD_UI
Z49QDT0J8Z	UNII
6321416	PUBCHEM_CID
5479529	PUBCHEM_CID
DB01112	DRUGBANK_ID
1053	MMSL
4388	MMSL
46962	MMSL
d00056	MMSL
002730	NDDF
003590	NDDF
372833007	SNOMEDCT_US
73986003	SNOMEDCT_US
89678001	SNOMEDCT_US
C0007562	UMLSCUI
D002444	MESH_DESCRIPTOR_UI
3902	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
CEFUROXIME AXETIL	HUMAN PRESCRIPTION DRUG LABEL	1	16590-215	TABLET, FILM COATED	500 mg	ORAL	ANDA	21 sections
Cefuroxime Axetil	Human Prescription Drug Label	1	16714-400	TABLET	250 mg	ORAL	ANDA	24 sections
Cefuroxime Axetil	Human Prescription Drug Label	1	16714-401	TABLET	500 mg	ORAL	ANDA	24 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	21695-150	TABLET	500 mg	ORAL	ANDA	25 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	21695-370	TABLET	250 mg	ORAL	ANDA	25 sections
cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-584	TABLET	250 mg	ORAL	ANDA	23 sections
Cefuroxime Axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-623	TABLET	250 mg	ORAL	ANDA	24 sections
Cefuroxime Axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-623	TABLET	250 mg	ORAL	ANDA	24 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-656	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-656	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-657	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-657	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime Axetil	Human Prescription Drug Label	1	50090-0781	TABLET	250 mg	ORAL	ANDA	24 sections
Cefuroxime axetil	Human Prescription Drug Label	1	50090-2157	TABLET, FILM COATED	500 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	Human Prescription Drug Label	1	50090-2158	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	Human Prescription Drug Label	1	50090-2159	TABLET, FILM COATED	250 mg	ORAL	ANDA	26 sections
Cefuroxime axetil	Human Prescription Drug Label	1	50090-2159	TABLET, FILM COATED	250 mg	ORAL	ANDA	26 sections
Cefuroxime Axetil	Human Prescription Drug Label	1	50090-4153	TABLET	500 mg	ORAL	ANDA	26 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	51407-333	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	51407-334	TABLET, FILM COATED	500 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	Human Prescription Drug Label	1	52959-308	TABLET, FILM COATED	250 mg	ORAL	ANDA	14 sections
Cefuroxime Axetil	Human Prescription Drug Label	1	52959-939	TABLET	500 mg	ORAL	ANDA	27 sections
Cefuroxime axetil	Human Prescription Drug Label	1	53002-2670	TABLET, FILM COATED	500 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	Human Prescription Drug Label	1	53002-2750	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime Axetil	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4987	TABLET	250 mg	ORAL	ANDA	14 sections
Cefuroxime Axetil	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5022	TABLET	500 mg	ORAL	ANDA	14 sections
Cefuroxime Axetil	HUMAN PRESCRIPTION DRUG LABEL	1	55289-385	TABLET, FILM COATED	250 mg	ORAL	ANDA	26 sections
Cefuroxime Axetil	HUMAN PRESCRIPTION DRUG LABEL	1	55648-920	TABLET, FILM COATED	125 mg	ORAL	ANDA	25 sections
Cefuroxime Axetil	HUMAN PRESCRIPTION DRUG LABEL	1	55648-921	TABLET, FILM COATED	250 mg	ORAL	ANDA	25 sections
Cefuroxime Axetil	HUMAN PRESCRIPTION DRUG LABEL	1	55648-922	TABLET, FILM COATED	500 mg	ORAL	ANDA	25 sections